EU to curb COVID-19 vaccine exports: report

0
19
EU to curb COVID-19 vaccine exports: report


The European Union is set to introduce emergency legislation that will allow it to control exports of COVID-19 vaccines amid a growing dispute over supplies that has threatened to derail vaccination efforts in the country. block of 27 members.

A draft of the rules is expected to be announced on Wednesday, according to the New York Times, which saw a copy and confirmed it with European sources. The legislation mainly aims to stop the exports of vaccines from AstraZeneca AZN,
-0,32%

AZN,
-3,52%
to the rest of the world.

The Anglo-Swedish drugmaker warned in January that it would not be able to meet its delivery obligations to the EU, due to manufacturing issues at some of its European factories. The lack of deliveries has led to a high-profile row with the EU, which has fallen behind countries like the US, UK and Israel in rolling out vaccines for its health workers and workers. most vulnerable people.
AstraZeneca has always said it was not legally bound to deliver to the EU on a specific schedule, as it had committed to supplying vaccines only under a “best effort” clause.

Last week, European Commission President Ursula von der Leyen threatened to use emergency powers to curb exports, as she pointed out that the EU had authorized the shipment of 41 million doses to 33 countries since early February. She said AstraZeneca over-promised and under-delivered its contract with the EU, although the same cannot be said of Pfizer-BioNTech PFE,
-1,78%

0Q1N,
-2,60%

BNTX,
-6,44%
and Modern MRNA,
-6,24%.

Read: Why strains on vaccine supply are unlikely to abate

The tightening of export rules is yet another setback for AstraZeneca after some countries temporarily suspended use of the vaccine due to concerns about blood clots in some recipients. Several countries have relaunched their inoculation campaigns after the European Medicines Agency last week declared the vaccine “safe and effective” after its own investigation found no link to blood clots.

AstraZeneca said its own review of safety data from more than 17 million people vaccinated in the UK and the European Union showed no evidence of an increased risk of blood clots.

Meanwhile, on Tuesday, AstraZeneca was accused by US health officials of including “outdated information” in a study of its vaccine. AstraZeneca has promised to share updated data with the United States within 48 hours.

LEAVE A REPLY

Please enter your comment!
Please enter your name here